Table 3.
Temporal associations between AKI and the mean annual change in eGFR by hemoglobin phenotype
| Outcomes | Normal Hemoglobin Phenotype | Sickle Cell Trait | Sickle Cell Disease |
|---|---|---|---|
| Median (IQR) number of eGFR values over follow-up | 44 (22–120) | 65 (25–157) | 237 (113–563) |
| Mean (SD) eGFR at baseline | 114.4 (27.4) | 103.7 (27.7) | 127.9 (35.7) |
| Adjusted mean annual change in eGFR pre-AKI (including patients who never had AKI) within each group (95% CI)a | −0.82 (−0.80 to −0.84) | −1.09 (−1.05 to −1.14) | −1.68 (−1.60 to −1.76) |
| Adjusted difference in mean annual change in eGFR pre-AKI (including patients who never had AKI) between groups (95% CI)a | 0 (reference) | −0.28 (−0.22 to −0.33) | −0.86 (−0.79 to −0.94) |
| Adjusted mean annual change in eGFR post-AKI within each group (95% CI)a | −1.63 (−1.56 to −1.69) | −2.00 (−1.85 to −2.14) | −3.31 (−3.10 to −3.53) |
| Adjusted difference in mean annual change in eGFR post-AKI between groups (95% CI)a | 0 (reference) | −0.37 (−0.21 to −0.54) | −1.69 (−1.51 to −1.88) |
| Adjusted difference between mean annual change in eGFR pre-AKI (including patients who never had AKI) and mean annual change in eGFR post-AKI within each group (95% CI)a | −0.81 (−0.76 to −0.87) | −0.90 (−0.78 to −1.03) | −1.63 (−1.44 to −1.82) |
IQR, interquartile range; 95% CI, 95% confidence interval.
a
All models were adjusted for baseline age, sex, hypertension, diabetes mellitus, cardiovascular disease, and renin-angiotensin-aldosterone system inhibitors. Hemoglobin electrophoresis indication was included in the sickle cell trait and normal hemoglobin phenotype (reference) models.